Previous 10 | Next 10 |
MALVERN, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that Institutional Shareholder Services, Inc. (ISS), t...
MALVERN, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that Glass Lewis & Co. has recommended that Baudax...
The following slide deck was published by Baudax Bio, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Baudax Bio, Inc. 2021 Q1 - Results - Earnings Call Presentation
Baudax Bio, Inc. (BXRX) Q1 2021 Results Earnings Conference Call May 05, 2021, 08:00 AM ET Company Participants Claudia Styslinger - Investor Relations Gerri Henwood - President and Chief Executive Officer Richard Casten - Chief Financial Officer Conference Call Participants Leland Gershell -...
Baudax Bio (BXRX): Q1 GAAP EPS of -$0.27 misses by $0.08.Revenue of $0.2M misses by $0.3M.As of March 31, 2021, Baudax Bio had cash, cash equivalents and short-term investments of $38.2 million.Press Release For further details see: Baudax Bio EPS misses by $0.08, misses on re...
ANJESO ® Demonstrates Continued Progress with Launch; Growth in End-User Unit Sales Increased 40% in Q1 compared to Q4’20 Average Sales per Account Increased 30% in Q1 compared to Q4’20 Richard S. Casten Strengthens Management Team in Chief...
MALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 202...
Baudax Bio (BXRX) announces data highlighting the safety and efficacy of preoperative Anjeso (meloxicam) injection in patients undergoing unilateral total knee arthroplasty ((TKA)) when used within a multimodal analgesic regimen, in the peer-reviewed medical journal Pain Medicine. During...
Patients Administered ANJESO Prior to the Start of Surgery had Significantly Lower Summed Pain Intensity Scores on the First Postsurgical Day and Throughout Their Inpatient Course ANJESO Treated TKA Patients Demonstrated Decreased Opioid Consumption Following Surgery, Particular...
MALVERN, Pa., April 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has adjourned its 2021 Annual Meeting of Shareholders (the “Annual Meeting&...
News, Short Squeeze, Breakout and More Instantly...
Baudax Bio Inc. Company Name:
BXRX Stock Symbol:
NYSE Market:
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Baudax Bio Inc. (BXRX) is expected to report $-0.53 for Q3 2023